Testing for t(3;8) in MYC/BCL6-rearranged large B-cell lymphoma identifies a high-risk subgroup with inferior survival

Blood. 2024 Jul 4;144(1):113-117. doi: 10.1182/blood.2024024048.

Abstract

A reciprocal t(3;8) BCL6::MYC fusion is common in large B-cell lymphoma (LBCL) with MYC and BCL6 disruption. These pseudo-double-hit cases are not adverse, whereas t(3;8)-MYC/BCL6 lymphoma has an inferior prognosis relative to other MYC-rearranged LBCL.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Gene Rearrangement
  • Humans
  • Lymphoma, Large B-Cell, Diffuse* / genetics
  • Lymphoma, Large B-Cell, Diffuse* / mortality
  • Lymphoma, Large B-Cell, Diffuse* / pathology
  • Male
  • Middle Aged
  • Oncogene Proteins, Fusion / genetics
  • Prognosis
  • Proto-Oncogene Proteins c-bcl-6* / genetics
  • Proto-Oncogene Proteins c-myc* / genetics
  • Translocation, Genetic*

Substances

  • Proto-Oncogene Proteins c-bcl-6
  • BCL6 protein, human
  • Proto-Oncogene Proteins c-myc
  • MYC protein, human
  • Oncogene Proteins, Fusion